S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:IRIX

IRIDEX (IRIX) Stock Price, News & Analysis

$2.95
+0.44 (+17.53%)
(As of 03/27/2024 ET)
Today's Range
$2.61
$3.10
50-Day Range
$2.35
$2.95
52-Week Range
$1.31
$3.48
Volume
257,502 shs
Average Volume
32,271 shs
Market Capitalization
$47.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

IRIDEX MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
32.2% Downside
$2.00 Price Target
Short Interest
Bearish
2.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of IRIDEX in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.01 out of 5 stars

Computer And Technology Sector

588th out of 589 stocks

Electromedical Equipment Industry

20th out of 20 stocks

IRIX stock logo

About IRIDEX Stock (NASDAQ:IRIX)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Stock Price History

IRIX Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Iridex: Q4 Earnings Snapshot
IRIDEX earnings preview: what to expect
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
IRIDEX (IRIX) Set to Announce Quarterly Earnings on Tuesday
Iridex Stock (NASDAQ:IRIX), Short Interest Report
Iridex: Q3 Earnings Insights
IRIDEX Corp IRIX
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
BYU, WE and IRIX among pre-market losers
See More Headlines
Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:IRIX
Employees
130
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-32.2%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-7,550,000.00
Pretax Margin
-14.13%

Debt

Sales & Book Value

Annual Sales
$56.97 million
Book Value
$1.08 per share

Miscellaneous

Free Float
15,241,000
Market Cap
$47.94 million
Optionable
Optionable
Beta
0.81

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

IRIX Stock Analysis - Frequently Asked Questions

What is IRIDEX's stock price target for 2024?

0 Wall Street research analysts have issued 1-year target prices for IRIDEX's stock. Their IRIX share price targets range from $2.00 to $2.00. On average, they predict the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 32.2%.
View analysts price targets for IRIX
or view top-rated stocks among Wall Street analysts.

How have IRIX shares performed in 2024?

IRIDEX's stock was trading at $2.81 at the beginning of 2024. Since then, IRIX stock has increased by 5.0% and is now trading at $2.95.
View the best growth stocks for 2024 here
.

When is IRIDEX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IRIX earnings forecast
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) released its quarterly earnings data on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The medical equipment provider earned $13.26 million during the quarter, compared to the consensus estimate of $11.90 million. IRIDEX had a negative net margin of 18.45% and a negative trailing twelve-month return on equity of 69.35%. During the same quarter last year, the business earned ($0.12) EPS.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include AMH Equity Ltd (2.44%), Dimensional Fund Advisors LP (0.30%), Citadel Advisors LLC (0.00%), Northern Trust Corp (0.17%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends
.

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRIX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners